Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 86 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Galcanezumab for the prophylaxis of episodic and chronic migraine	Galcanezumab (Emgality; LY-2951742)	Migraine	Neurology	2017	View \| Download
Gantenerumab for Alzheimer’s disease	Gantenerumab	Alzheimer's disease	Neurology	2022	View \| Download
Human immunoglobulin with recombinant human hyaluronidase maintenance therapy for treating multifocal motor neuropathy	Human Immunoglobulin (TAK-771)	Multifocal motor neuropathy	Neurology	2024	View \| Download
Hydromethylthionine mesylate for Alzheimer's disease	Hydromethylthionine mesylate (LMTX;TRx-0237)	Alzheimer's disease	Neurology	2023	View \| Download
Inebilizumab for Neuromyelitis optica	Inebilizumab (MEDI551)	Neuromyelitis optica , Neuromyelitis optica spectrum disorders	Neurology , Ophthalmology	2018	View \| Download
Inebilizumab for neuromyelitis optica spectrum disorders	Inebilizumab (MEDI551)	Neuromyelitis optica spectrum disorders	Neurology	2024	View \| Download
Iptacopan for treating complement 3 glomerulopathy	Iptacopan	Complement 3 glomerulopathy	Immunology , Neurology	2023	View \| Download
Istradefylline for patients with Parkinson’s disease experiencing end of dose fluctuations	Istradefylline (Nouriast; KW-6002)	Parkinson's disease	Neurology	2020	View \| Download
Lacosamide for primary generalised tonic-clonic seizures – adjunctive therapy	Lacosamide (Vimpat)	Epilepsy	Neurology	2019	View \| Download
Lasmiditan for acute treatment of migraine	Lasmiditan (COL-144; LY573144)	Migraine	Neurology	2020	View \| Download